A clinical trial of an investigational compound for treatment of multiple myeloma is moving forward. 

Natalie Callander, MD, professor (CHS), Hematology, Medical Oncology and Palliative Care, was quoted in a press release about a phase I clinical trial of CLR 131 in relapsed or refractory multiple myeloma. 

The agent, which is being developed by Cellectar Biosciences, Inc. of Madison, Wisconsin, is an investigational compound under development for a range of hematologic malignancies. 

“Given the encouraging results we’ve observed to date in previous cohorts, we hope to see similar, or perhaps even improved safety results in this arm of the trial,” said Dr. Callander. 

Resources:

• "Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma," MarketsInsider, October 24, 2017